cusp06

CUSP06 is a cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC) developed for the treatment of platinum-refractory/resistant ovarian cancer and other advanced solid tumors. It consists of a proprietary human IgG1 monoclonal antibody with high affinity for CDH6, conjugated via a protease-cleavable linker to an exatecan payload—a potent topoisomerase I inhibitor. The design enables targeted delivery and intracellular release of the cytotoxic agent upon binding and internalization into CDH6-expressing tumor cells. This approach aims to maximize antitumor activity while minimizing systemic toxicity by focusing drug action on tumor cells that overexpress CDH6. Preclinical studies have shown CUSP06 induces tumor regression in both high and low CDH6-expressing models of ovarian cancer and other solid tumors. The drug is currently being evaluated in phase 1 clinical trials for platinum-resistant ovarian cancer, renal cell carcinoma, cholangiocarcinoma, hepatocellular carcinoma, papillary thyroid cancer, glioma, uterine serous carcinoma, non-small cell lung cancer (NSCLC), and other advanced solid tumors[1][2][3][5][6].

Other names

AMT-707AMT707AMT 707CUSP-06CUSP06CUSP 06